Opus advises Bain Capital and Cinven on their acquisition of Lonza Specialty Ingredients

Category: Deal Announcement

Opus Corporate Finance LLP advises Bain Capital and Cinven on their joint acquisition of Lonza Specialty Ingredients (“LSI”), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion.

Opus is pleased to have advised Bain Capital and Cinven on entering into a definitive agreement to acquire LSI, a world-leading provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. LSI’s products are critical ingredients in disinfectants, preservatives, sanitisers, personal care products, as well as coatings and other industrial uses. LSI also offers the custom development and manufacturing of specialty chemicals and composites for electronics, aerospace, food and agrochemical industries.

Headquartered in Basel, Switzerland, LSI has approximately 2,800 employees, 11 R&D centres and 17 manufacturing sites across the world serving circa 5,300 customers.

The transaction is expected to close in H2 2021, subject to customary closing conditions.

This is another market leading transaction and a significant milestone in the development of Opus’ Chemicals franchise.

For further information please contact: Chris Carlisle, Keegan Harris and Joanna Chen.